Diabet2 s.r.o.
- Address
- lock Available on a paid plan
Cardiovascular Disease Research
At Diabet2 s.r.o. in Prague, clinical trials in cardiovascular diseases focus on people at high risk of serious heart and blood vessel events. The studies are designed to evaluate whether new therapies can better prevent outcomes such as heart attack, stroke, and other major vascular complications.
- Atherosclerotic cardiovascular disease and related high-risk heart conditions
- Elevated lipoprotein(a) as a target for reducing cardiovascular risk
- Testing treatments intended to lower the chance of major events like myocardial infarction and ischemic stroke
The research includes adults with established or elevated atherosclerotic cardiovascular disease risk, with the goal of improving long-term prevention and treatment effectiveness.
Nutritional and Metabolic Disease Research
Another major area at this site is nutritional and metabolic diseases, with trials centered on type 2 diabetes mellitus, obesity, and overweight. These studies look at whether newer therapies can improve blood sugar control, support weight loss, and help manage cardiometabolic risk.
- Type 2 diabetes with overweight or obesity
- Evaluating treatments that may improve HbA1c and overall metabolic health
- Studying approaches that combine diabetes care with weight management
The clinical research at Diabet2 s.r.o. reflects a strong interest in therapies that address both diabetes and the broader metabolic conditions often linked to it.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diabet2 s.r.o.
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A single arm study investigating the glycaemic control and safety of adding semaglutide to insulin icodec in participants with type 2 diabetes qualifying for treatment intensification. | Novo Nordisk A/S | Phase III | Not Recruiting | Jan 2024 | May 2025 |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 3 | Unknown | 2022-08-31 | 2024-01-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.